176 related articles for article (PubMed ID: 19694729)
1. Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha.
Huang XS; Zhao SP; Bai L; Hu M; Zhao W; Zhang Q
Br J Pharmacol; 2009 Oct; 158(3):706-12. PubMed ID: 19694729
[TBL] [Abstract][Full Text] [Related]
2. [Statin reduced triglyceride level via activating peroxisome proliferator activated receptor α and upregulating apolipoprotein A5 in hypertriglyceridemic rats].
HUANG XS; ZHAO SP; BAI L; ZHANG Q; HU M; ZHAO W
Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Sep; 38(9):809-13. PubMed ID: 21092650
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats.
Roglans N; Sanguino E; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
J Pharmacol Exp Ther; 2002 Jul; 302(1):232-9. PubMed ID: 12065722
[TBL] [Abstract][Full Text] [Related]
4. The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
Black RN; Ennis CN; Young IS; Hunter SJ; Atkinson AB; Bell PM
J Diabetes Complications; 2014; 28(3):323-7. PubMed ID: 24560135
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4.
Sanguino E; Roglans N; Alegret M; Sánchez RM; Vázquez-Carrera M; Laguna JC
Br J Pharmacol; 2005 Aug; 145(7):853-61. PubMed ID: 15912134
[TBL] [Abstract][Full Text] [Related]
6. Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression.
Pierno S; Camerino GM; Cippone V; Rolland JF; Desaphy JF; De Luca A; Liantonio A; Bianco G; Kunic JD; George AL; Conte Camerino D
Br J Pharmacol; 2009 Apr; 156(8):1206-15. PubMed ID: 19220292
[TBL] [Abstract][Full Text] [Related]
7. Triglyceridemia and peroxisome proliferator-activated receptor-alpha expression are not connected in fenofibrate-treated pregnant rats.
Soria A; González Mdel C; Vidal H; Herrera E; Bocos C
Mol Cell Biochem; 2005 May; 273(1-2):97-107. PubMed ID: 16013444
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin might inhibit insulin resistance induced by insulin through the triglyceride-lowering role of Apolipoprotein AV.
Zhao W; Zhao SP
Eur Rev Med Pharmacol Sci; 2015 Oct; 19(20):3895-903. PubMed ID: 26531276
[TBL] [Abstract][Full Text] [Related]
9. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
Krause BR; Newton RS
Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869
[TBL] [Abstract][Full Text] [Related]
10. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment.
Vilà L; Rebollo A; Ađalsteisson GS; Alegret M; Merlos M; Roglans N; Laguna JC
Toxicol Appl Pharmacol; 2011 Feb; 251(1):32-40. PubMed ID: 21122807
[TBL] [Abstract][Full Text] [Related]
11. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
Lemieux I; Salomon H; Després JP
Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression.
Moon JH; Kang SB; Park JS; Lee BW; Kang ES; Ahn CW; Lee HC; Cha BS
Metabolism; 2011 Jul; 60(7):930-40. PubMed ID: 20951395
[TBL] [Abstract][Full Text] [Related]
13. [A dyslipidemia animal model induced by poloxamer 407 in golden hamsters and pilot study on the mechanism].
Liu Q; Liu SN; Li LY; Chen ZY; Lei L; Zhang N; Shen ZF
Yao Xue Xue Bao; 2011 Apr; 46(4):406-11. PubMed ID: 21751494
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
Chan DC; Watts GF; Ooi EM; Ji J; Johnson AG; Barrett PH
Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1831-7. PubMed ID: 18566295
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats.
Dorfmeister B; Brandlhofer S; Schaap FG; Hermann M; Fürnsinn C; Hagerty BP; Stangl H; Patsch W; Strobl W
Diabetologia; 2006 Jun; 49(6):1324-32. PubMed ID: 16570166
[TBL] [Abstract][Full Text] [Related]
16. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.
Kockx M; Gervois PP; Poulain P; Derudas B; Peters JM; Gonzalez FJ; Princen HM; Kooistra T; Staels B
Blood; 1999 May; 93(9):2991-8. PubMed ID: 10216095
[TBL] [Abstract][Full Text] [Related]
17. Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia.
Okopien B; Huzarska M; Kulach A; Stachura-Kulach A; Madej A; Belowski D; Zielinski M; Herman ZS
J Cardiovasc Pharmacol; 2005 Feb; 45(2):160-4. PubMed ID: 15654265
[TBL] [Abstract][Full Text] [Related]
18. Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia.
Melenovsky V; Wichterle D; Simek J; Malik J; Haas T; Ceska R; Malik M
Am J Cardiol; 2003 Aug; 92(3):337-41. PubMed ID: 12888150
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor.
Funatsu T; Kakuta H; Takasu T; Miyata K
Eur J Pharmacol; 2002 Nov; 455(2-3):161-7. PubMed ID: 12445582
[TBL] [Abstract][Full Text] [Related]
20. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element.
Prieur X; Coste H; Rodriguez JC
J Biol Chem; 2003 Jul; 278(28):25468-80. PubMed ID: 12709436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
